Vincent Wai-Hin Yuen

Vincent Wai-Hin Yuen

Auto-generated profile, based on publicly available information

Vincent Wai-Hin Yuen

Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
VYVincent Wai-Hin Yuen
Vincent Wai-Hin Yuen
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
The liver has strong innate immunity to counteract pathogens from the gastrointestinal tract. During the development of liver cancer, which is typically driven by chronic inflammation, the composition and biological roles of the innate immune cells are extensively altered. Hypoxia is a common finding in all stages of liver cancer development. Hypoxia drives the stabilization of hypoxia-inducible factors (HIFs), which act as central regulators to dampen the innate immunity of liver cancer. HIF signaling in innate immune cells and liver cancer cells together favors the recruitment and maintenance of pro-tumorigenic immune cells and the inhibition of anti-tumorigenic immune cells, promoting immune evasion. HIFs represent attractive therapeutic targets to inhibit the formation of an immunosuppressive microenvironment and growth of liver cancer.

5 May 2023 in Science Advances
Verified
Journal Article
Open access
JCJacinth Wing-Sum Cheu
Jacinth Wing-Sum Cheu
DCDavid Kung-Chun Chiu
David Kung-Chun Chiu
KKKenneth Kin-Leung Kwan
Kenneth Kin-Leung Kwan
CYChunxue Yang
Chunxue Yang
VYVincent Wai-Hin Yuen
Vincent Wai-Hin Yuen
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
Hypoxia-induced adenosine creates an immunosuppressive tumor microenvironment (TME) and dampens the efficacy of immune checkpoint inhibitors (ICIs). We found that hypoxia-inducible factor 1 (HIF-1) orchestrates adenosine efflux through two steps in hepatocellular carcinoma (HCC). First, HIF-1 activates transcriptional repressor MXI1, which inhibits adenosine kinase (ADK), resulting in the failure of adenosine phosphorylation to adenosine monophosphate. This leads to adenosine accumulation in hypoxic cancer cells. Second, HIF-1 transcriptionally activates equilibrative nucleoside transporter 4, pumping adenosine into the interstitial space of HCC, elevating extracellular adenosine levels. Multiple in vitro assays demonstrated the immunosuppressive role of adenosine on T cells and myeloid cells. Knockout of ADK in vivo skewed intratumoral immune cells to protumorigenic and promoted tumor progression. Therapeutically, combination treatment of adenosine receptor antagonists and anti–PD-1 prolonged survival of HCC-bearing mice. We illustrated the dual role of hypoxia in establishing an adenosine-mediated immunosuppressive TME and offered a potential therapeutic approach that synergizes with ICIs in HCC.

28 November 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
VYVincent Wai-Hin Yuen
Vincent Wai-Hin Yuen
DCDavid Kung-Chun Chiu
David Kung-Chun Chiu
CLCheuk-Ting Law
Cheuk-Ting Law
JCJacinth Wing-Sum Cheu
Jacinth Wing-Sum Cheu
CCCerise Yuen-Ki Chan
Cerise Yuen-Ki Chan
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong

30 October 2022 in Advanced Science
Verified
Journal Article
Open access
CYChunxue Yang
Chunxue Yang
DLDerek Lee
Derek Lee
MZMisty Shuo Zhang
Misty Shuo Zhang
ATAki Pui‐Wah Tse
Aki Pui‐Wah Tse
LWLai Wei
Lai Wei
CWCarmen Chak‐Lui Wong
Carmen Chak‐Lui Wong
Hepatocellular carcinoma (HCC) is the second most lethal cancer worldwide. Glutamine is an essential, extracellular nutrient which supports HCC growth. Dietary glutamine deficiency may be a potential therapeutic approach for HCC. HCC cells overcome metabolic challenges by rewiring their metabolic pathways for rapid adaptations. The efficiency of dietary glutamine deficiency as HCC treatment is examined and the adaptation machinery under glutamine depletion in HCC cells is unraveled. Using genome‐wide CRISPR/Cas9 knockout library screening, this study identifies that pyruvate dehydrogenase α (PDHA), pyruvate dehydrogenase β (PDHB), and pyruvate carboxylase (PC) in pyruvate metabolism are crucial to the adaptation of glutamine depletion in HCC cells. Knockout of either PDHA, PDHB or PC induced metabolic reprogramming of the tricarboxylic acid (TCA) cycle, disrupts mitochondrial function, leading to the suppression of HCC cell proliferation under glutamine depletion. Surprisingly, dietary glutamine restriction improves therapeutic responses of HCC to PDH or PC inhibitor in mouse HCC models. Stable isotope carbon tracing confirms that PDH or PC inhibitors further disrupt the metabolic rewiring of the TCA cycle induced by dietary glutamine depletion in HCC. In summary, the results demonstrate that pyruvate metabolism acts as novel targetable metabolic vulnerabilities for HCC treatment in combination with a glutamine‐deficient diet.